- Annovis Bio (ANVS) has priced its initial public offering of 2M common shares at $6.00 per share, for gross proceeds of $12M.
- More news on: Annovis Bio, Healthcare stocks news, IPO News, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Annovis announced in June 2024 that they had filed a composition of matter patent for their new crystal form of buntanetap, along with a provisional patent for the manufacturing process The company’s goal is to use this technology to restore brain function and improve the quality of life...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...